VTGN250117P10000
- 0.00
- 0.000.00%
VistaGen Therapeutics Newsroom
Stifel Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
VistaGen Therapeutics' Promising Clinical Progress and Strong Financial Position Justify Buy Rating
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Maxim Group Maintains VistaGen Therapeutics(VTGN.US) With Buy Rating, Maintains Target Price $12
Buy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)
Vistagen Therapeutics Analyst Ratings
Hearing Vistagen Therapeutics Upgraded From A Hold To A Buy At Jefferies; Price Target $15
Vistagen Therapeutics Analyst Ratings
VistaGen Therapeutics' Robust Financial Position and Promising Pipeline Underpin Buy Rating: A Comprehensive Analysis
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Rhythm Pharmaceuticals (RYTM)
Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating
Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target
Vistagen Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Humacyte (HUMA)
Maxim Group Sticks to Their Hold Rating for VistaGen Therapeutics (VTGN)
Maxim Group Sticks to Its Hold Rating for VistaGen Therapeutics (VTGN)
Robert W. Baird Reaffirms Their Hold Rating on VistaGen Therapeutics (VTGN)
Maxim Group Remains a Hold on VistaGen Therapeutics (VTGN)
VistaGen Therapeutics Cut to Hold From Buy by Maxim Group